Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 9/20 | 0.65 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.65 |
| ▸ | COQ8A | Q8NI60 | 4/20 | 0.65 |
| ▸ | NLK | Q9UBE8 | 4/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.59 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.47 |
| ▸ | NEK4 | P51957 | 1/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.47 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.47 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633676 | 0.86 | GAK (0.68) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL25466634 | 0.82 | GAK (0.70) | GAKRIPK2COQ8ANLKHTR1A | |
| Hydrochloric Acid SCHEMBL9073104 | 0.81 | GAK (0.58) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL30420525 | 0.81 | HTT (0.70) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL19633637 | 0.81 | GAK (0.64) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL19633703 | 0.80 | GAK (0.60) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL25466706 | 0.80 | GAK (0.67) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL30420470 | 0.80 | GAK (0.67) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL21121679 | 0.80 | HTT (0.64) | GAKRIPK2COQ8ANLKHTR1A | |
| SCHEMBL21121509 | 0.80 | HTT (0.64) | GAKRIPK2COQ8ANLKHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557816-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776857-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2137177-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124083-A2 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336182-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, CDK1 | GAK 62/4885RIPK2 533/4885COQ8A 290/4885 |
| US-20090069297-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | GAK 62/4885RIPK2 533/4885COQ8A 290/4885 |
| US-20100280008-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | GAK 62/4885RIPK2 533/4885COQ8A 290/4885 |
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | GAK 62/4885RIPK2 533/4885COQ8A 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.